Supplements

Lansoprazole discontinuation improves restless legs syndrome and periodic limb movement disorder symptoms in a hemodialysis patient

A 76-year-old hemodialysis patient with dopaminergic-refractory RLS/PLMD experienced near-complete symptom resolution within 14 days after discontinuing lansoprazole and switching to vonoprazan. The RLS-6 score dropped from 28 to 4, and the Naranjo score was 5, indicating a probable adverse drug reaction.

1 min readUpdated Jul 7, 20260 RCTsView structured evidence →
Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism☆☆☆☆☆
Safety☆☆☆☆☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Lansoprazole discontinuation improves restless legs syndrome and periodic limb movement disorder symptoms in a hemodialysis patient The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).

The Claim

Lansoprazole discontinuation improves restless legs syndrome and periodic limb movement disorder symptoms in a hemodialysis patient

This conclusion is most relevant to: A 76-year-old female hemodialysis patient with end-stage renal disease due to diabetic nephropathy and peptic ulcer disease.

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • Lansoprazole as a possible trigger of restless legs syndrome with suspected periodic limb movement disorder in a hemodialysis patient: a case report. (CEN case reports, 2026) —

How It Works

The proposed biological pathway:

  • Lansoprazole may alter iron or magnesium homeostasis in hemodialysis patients
  • Disruption of dopaminergic pathways or other neurotransmitter systems
  • Accumulation of drug or metabolites due to renal impairment
  • Result: Exacerbation or induction of RLS/PLMD symptoms

Who Might Benefit

Evidence fit by population:

  • A 76-year-old female hemodialysis patient with end-stage renal disease due to diabetic nephropathy and peptic ulcer disease

Limitations & Caveats

Important context when interpreting this evidence:

  • Single case report, not generalizable to broader populations
  • Confounding by prior discontinuation of methyldopa, which partially improved symptoms
  • No objective polysomnography or actigraphy to confirm PLMD

References

  1. 1.Nakata H, Nishiwaki K. “Lansoprazole as a possible trigger of restless legs syndrome with suspected periodic limb movement disorder in a hemodialysis patient: a case report..” CEN case reports, 2026. PMID: 41999568 DOI: 10.1007/s13730-026-01099-1
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.